A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
Identifieur interne : 000841 ( Main/Exploration ); précédent : 000840; suivant : 000842A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
Auteurs : Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-08-15.
English descriptors
- KwdEn :
Abstract
Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double‐blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23148
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23148</idno><idno type="url">https://api.istex.fr/document/7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002268</idno><idno type="wicri:Area/Main/Curation">001F53</idno><idno type="wicri:Area/Main/Exploration">000841</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Neurology Department, Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch Hospital, Christchurch</wicri:regionArea><wicri:noRegion>Christchurch</wicri:noRegion></affiliation></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Medicine, Neurology Research Centre and University of Queensland Clinical School, Royal Brisbane & Women's Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Neurology, Westmead Hospital, Sydney Medical School, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement></placeName></affiliation></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Chemistry Department, University of Otago, Dunedin</wicri:regionArea><wicri:noRegion>Dunedin</wicri:noRegion></affiliation></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Mitochondrial Biology Unit, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1670">1670</biblScope><biblScope unit="page" to="1674">1674</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82</idno><idno type="DOI">10.1002/mds.23148</idno><idno type="ArticleID">MDS23148</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MitoQ</term><term>PD</term><term>mitochondria</term><term>neuroprotection</term><term>oxidative damage</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double‐blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Australie</li><li>Nouvelle-Zélande</li><li>Royaume-Uni</li></country><settlement><li>Sydney</li></settlement></list><tree><country name="Nouvelle-Zélande"><noRegion><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name></noRegion><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name></country><country name="Australie"><noRegion><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name></noRegion><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000841 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000841 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82
|texte= A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |